Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enveric Biosciences Inc (ENVB)

Enveric Biosciences Inc (ENVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,767
  • Shares Outstanding, K 1,390
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,570 K
  • EBIT $ -10 M
  • EBITDA $ -9 M
  • 60-Month Beta 0.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.30

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.8200 +9.34%
on 03/09/26
2.4700 -19.43%
on 02/25/26
-0.1200 (-5.69%)
since 02/09/26
3-Month
1.8200 +9.34%
on 03/09/26
13.2500 -84.98%
on 12/10/25
-3.9300 (-66.39%)
since 12/09/25
52-Week
1.8200 +9.34%
on 03/09/26
22.2000 -91.04%
on 03/17/25
-19.8500 (-90.89%)
since 03/07/25

Most Recent Stories

More News
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

ENVB : 1.9900 (+2.31%)
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

Proprietary assays demonstrate dual Gq and β-arrestin signaling at 5-HT₂ A , pathways linked in peer-reviewed studies to antidepressant and anxiolytic effects ...

ENVB : 1.9900 (+2.31%)
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

RCANN ™ Trademark Portfolio Out-Licensed

ENVB : 1.9900 (+2.31%)
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological...

ENVB : 1.9900 (+2.31%)
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological...

ENVB : 1.9900 (+2.31%)
Enveric Biosciences Announces Patent Issuance

U.S. Patent expands the scope of patent protection and increases the number of molecules that Enveric has the potential to develop or license for the treatment of neuropsychiatric conditions.

ENVB : 1.9900 (+2.31%)
ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of...

ENVB : 1.9900 (+2.31%)
FEED : 1.9300 (-3.98%)
Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological...

ENVB : 1.9900 (+2.31%)
Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological...

ENVB : 1.9900 (+2.31%)
Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

Once issued, this new U.S. Patent will expand the scope of Enveric’s EVM301 patent portfolio of potential neuroplastogenic molecules for treatment of neuropsychiatric conditions.

ENVB : 1.9900 (+2.31%)

Business Summary

Enveric Biosciences Inc. is a patient-centric biotechnology company endeavoring to enhance the lives of Cancer Treatments with novel cannabinoid medicines. Enveric Biosciences Inc., formerly known as AMERI Holdings Inc., is based in NAPLES, Fla.

See More

Key Turning Points

3rd Resistance Point 2.2167
2nd Resistance Point 2.1033
1st Resistance Point 2.0467
Last Price 1.9900
1st Support Level 1.8767
2nd Support Level 1.7633
3rd Support Level 1.7067

See More

52-Week High 22.2000
Fibonacci 61.8% 14.4148
Fibonacci 50% 12.0100
Fibonacci 38.2% 9.6052
Last Price 1.9900
52-Week Low 1.8200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar